BIOPHARM GmbH
Development of biotechnological medicines
The company was founded by Michael Paulista in 1968. Before moving to Eppelheim, the company was located in the Heidelberg Technology Park (Rhine Neckar Triangle BioRegion).
Michael Paulista, owner and founder
Jens Pohl, Dr., CEO
Rolf Bechtold, Dr.
Stefan Künzig, Dipl. Ing.
Benedikt Merz, Dr.
Czernyring 22
69115 Heidelberg
Germany
Phone: +49-6221-53-83-0
Fax: +49-6221-53-83-20
GDF-5 is a protein which functions as a growth and differentiation factor, particularly for bone, cartilage and nerve tissue. BIOPHARM has decoded and isolated the nucleotide sequence on the human genome and then introduced the isolated gene sequences into the genome of suitable bacteria, thus causing these cells to produce GDF-5 (expression). BIOPHARM has developed suitable methods for the preparation of pure recombinant human GDF-5 (abbreviated as rhGDF-5).
The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.
Related patents
- Targeted Compounds with Cartilage Formation-Inducing and/or Bone Formation-Inducing Activity
- Anti-Human MP52 Monoclonal Antibody
- Verbindungen mit Verbesserter Knorpel- und/oder Knocheninduzierender Aktivität
- Pharmaceutical Composition and Diagnostic Kit Directed to a Heterologeneous Pathogenic Organism in a Host
- Method of Treatment with Growth/Differentiation Factors of the TGF-beta Family
- Process for Preparing Purified Dimer of Bone-derived Factor
- Cartilage/bone Inducing Materials for Preparation
- Use of TGF-beta Inhibitors for Treating Cerebral Disorders
- Neuroprotective Properties of GDF-15, a Member of the TGF-Beta Superfamily
- Human BMP-2 Promoter and Method for Exploring Bone-related Substance by Using the Same
- Use of GDNF for Treating Corneal Defects
- Lyophilized Composition of Bone Morphogenetic Factor Human MP52
- Use of TGF-beta Inhibitors for Treating Cerebral Disorders
- DNA Sequences Encoding Novel Growth/Differentiation Factors
- Bone Morphogenetic Protein Antagonist Based on the Mature Protein
- Novel Protein and Process for Producing the Same
- Novel Protein and Process for Producing the Same
- Monomer Protein with Bone Morphogenetic Activity and Medicinal Agent Containing the Same for Preventing and Treating Diseases of Cartilage and Bone
- Neuroprotective Properties of GDF-15, a Novel Member of the TGF- Beta Superfamily
- Cartilage/bone Inducing Materials for Preparation
- Compounds with Improved Cartilage-inducing and/or Bone-inducing Activity
- Improved Osteoinductive Materials
- Improved Osteoinductive Materials
- Freeze-Dried Composition of Bone Morphogenetic Protein Human Mp52
- MP121, a Growth/Differentiation Factor of the TGF-beta Family
- Pharmaceutical Composition for Curing or Preventing Injury to Skin or Mucous Membrane, and for Healing Process of Wound and Tissue Regenerating Process
- Use of Cytokines of the TGF-beta Superfamily for the Treatment and Diagnosis of Skin Related Disorders
- Antibody or Antibody Fragments Specific for a Protein of the TGF-beta Family
- DNA Sequences Encoding Novel Growth/Differentiation Factors
- New Growth/Differentiation Factor of the TGF--g(b) Family
- EGF-Like Factor From Chromaffin Granules and Glia Cell-Derived Neurotrophic Factor...
- Cytokines Having Neurotrophic Activity
- Novel Protein and Process for Preparing the Same
- EGF-Like Factor From Chromaffin Granules and Glia Cell-Derived Neurotrophic Factor...
- Pharmaceutical Composition and Diagnostic Kit Directed to a Heterologeneous Pathogenic Organism in a Host